JP2022549171A5 - - Google Patents

Info

Publication number
JP2022549171A5
JP2022549171A5 JP2022517446A JP2022517446A JP2022549171A5 JP 2022549171 A5 JP2022549171 A5 JP 2022549171A5 JP 2022517446 A JP2022517446 A JP 2022517446A JP 2022517446 A JP2022517446 A JP 2022517446A JP 2022549171 A5 JP2022549171 A5 JP 2022549171A5
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
member heterocycloalkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549171A (ja
JP7642619B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/116510 external-priority patent/WO2021052499A1/zh
Publication of JP2022549171A publication Critical patent/JP2022549171A/ja
Publication of JP2022549171A5 publication Critical patent/JP2022549171A5/ja
Application granted granted Critical
Publication of JP7642619B2 publication Critical patent/JP7642619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517446A 2019-09-20 2020-09-21 縮合ピリドン化合物、ならびにその調製方法および使用 Active JP7642619B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201910892032.X 2019-09-20
CN201911129688.2 2019-11-18
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN201911157939.8 2019-11-22
CN202010054188 2020-01-17
CN202010054188.3 2020-01-17
CN202010102546 2020-02-19
CN202010102546.3 2020-02-19
CN202010230303 2020-03-27
CN202010230303.8 2020-03-27
CN202010306926 2020-04-17
CN202010306926.9 2020-04-17
CN202010367694 2020-04-30
CN202010367694.8 2020-04-30
CN202010967317.8 2020-09-15
CN202010967317 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2022549171A JP2022549171A (ja) 2022-11-24
JP2022549171A5 true JP2022549171A5 (https=) 2023-09-28
JP7642619B2 JP7642619B2 (ja) 2025-03-10

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517446A Active JP7642619B2 (ja) 2019-09-20 2020-09-21 縮合ピリドン化合物、ならびにその調製方法および使用

Country Status (15)

Country Link
US (1) US20220389029A1 (https=)
EP (1) EP4043464A4 (https=)
JP (1) JP7642619B2 (https=)
KR (1) KR20220086573A (https=)
CN (5) CN118619971A (https=)
AU (1) AU2020350745B2 (https=)
BR (1) BR112022005193A2 (https=)
CA (1) CA3155066A1 (https=)
CL (1) CL2022000666A1 (https=)
CO (1) CO2022004686A2 (https=)
IL (1) IL291467B1 (https=)
MX (1) MX2022003401A (https=)
PH (1) PH12022550681A1 (https=)
TW (1) TWI761961B (https=)
WO (1) WO2021052499A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
JP7601869B2 (ja) * 2019-10-30 2024-12-17 ▲勁▼方医▲薬▼科技(上海)有限公司 置換された複素環-環系化合物、その調製方法及び医薬への応用
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras抑制劑
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021197499A1 (zh) * 2020-04-03 2021-10-07 南京明德新药研发有限公司 八氢吡嗪并二氮杂萘啶二酮类化生物
WO2022037630A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
CA3194067A1 (en) 2020-09-15 2022-03-24 Revolution Medicines, Inc. Ras inhibitors
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Fgfr抑制劑及其製造及使用方法
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス, インコーポレイテッド アザキナゾリン汎KRas阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022143995A1 (zh) * 2020-12-31 2022-07-07 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
CN116964056B (zh) * 2021-03-25 2026-04-10 上海济煜医药科技股份有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
CN116848111A (zh) * 2021-03-26 2023-10-03 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
CN117222654A (zh) * 2021-09-06 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
WO2023116895A1 (zh) * 2021-12-24 2023-06-29 劲方医药科技(上海)有限公司 Kras抑制剂的多晶型物及其制备方法和用途
CN121466307A (zh) * 2022-04-01 2026-02-06 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2025016436A1 (zh) * 2023-07-19 2025-01-23 上海济煜医药科技有限公司 Kras抑制剂的制备方法、其中间体和其中间体的制备方法
CN121773111A (zh) * 2023-08-15 2026-03-31 劲方医药科技(上海)股份有限公司 吡嗪并萘啶二酮类化合物的制备方法及其中间体
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥(無錫)有限公司 癌症治療的療法
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025256521A1 (zh) * 2024-06-11 2025-12-18 上海济煜医药科技有限公司 作为kras抑制剂的稠合吡啶酮类化合物的制备方法、中间体及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3055290B1 (en) * 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) * 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
KR20180081596A (ko) * 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US20200010479A1 (en) * 2017-02-03 2020-01-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
AU2018273356B2 (en) * 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US10597405B2 (en) * 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
EP3842433B1 (en) * 2018-01-19 2023-11-01 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
CA3098574A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3919483A4 (en) * 2019-01-29 2022-02-09 Brightgene Bio-medical Technology Co., Ltd. HETEROCYCLIC BENZOPYRIDONE COMPOUND AND USE THEREOF
CN113396147B (zh) * 2019-05-31 2024-06-18 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
JP7601869B2 (ja) * 2019-10-30 2024-12-17 ▲勁▼方医▲薬▼科技(上海)有限公司 置換された複素環-環系化合物、その調製方法及び医薬への応用

Similar Documents

Publication Publication Date Title
JP2022549171A5 (https=)
JP2022543767A5 (https=)
TWI864048B (zh) 抗病毒雜環化合物、其醫藥組成物及其用途
CN101268073A (zh) 杂环化合物、制备方法及其用途
TW200914441A (en) Process for synthesizing compounds useful for treating hepatitis C
CN107312009B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
CN110582500B (zh) 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
WO2019154366A1 (zh) 含氮杂环类化合物及其制备方法和用途
CN103124730A (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2002535331A (ja) 新規血管形成阻害薬
JP2008514643A5 (https=)
JP2013536235A5 (https=)
US8399668B2 (en) Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides
TW202024093A (zh) 作為抗病毒劑之官能化雜環
TW201741303A (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
CN105473573A (zh) 用作激酶抑制剂的咔唑甲酰胺化合物
JP7530510B2 (ja) Rnaヘリカーゼdhx33を阻害する多環式化合物及びその応用
TWI424998B (zh) 作為腺苷A3受體配體的三唑并[1,5-a]喹啉類
CN115073450A (zh) Krasg12c突变蛋白抑制剂的制备及其应用
TW201242955A (en) Nitrogen-containing heterocyclic compound
AU2021342777A9 (en) 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
WO2021121420A1 (zh) 苯并吡唑类化合物及其中间体、制备方法和应用
TW201124411A (en) The manufacturing method of 6-substituted-1-methy-1H-benzimidazol derivatives and the synthesis intermediates thereof
JP2019501126A5 (https=)
EP4568971A1 (en) Antagonists of 5-hydroxytryptamine receptor subtype 2b